PD-1 INHIBITOR
Clinical trials for PD-1 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PD-1 INHIBITOR trials appear
Sign up with your email to follow new studies for PD-1 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New triple therapy hopes to outsmart tough esophageal cancer
Disease control Not yet recruitingThis study tests a new three-drug combination for people with advanced esophageal squamous cell carcinoma (ESCC). The drugs include a targeted therapy (becotatug vedotin), an immunotherapy (tislelizumab), and standard chemotherapy. The goal is to see if this combo shrinks tumors …
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 10:51 UTC
-
New combo therapy aims to shrink rectal tumors before surgery
Disease control Not yet recruitingThis study tests whether a short course of radiation, while keeping certain lymph nodes intact, followed by an immunotherapy drug (PD-1 inhibitor) can completely eliminate rectal cancer before surgery. It involves 44 adults with stage II-III rectal cancer. The goal is to see if t…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 10:46 UTC